Sorrento Therapeutics Inc. [NASDAQ: SRNE] stock went on a downward path that fall over -1.18% on Friday, amounting to a one-week price increase of more than 17.21%. The company report on November 11, 2020 that Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2.
IND filing for STI-2099 (COVI-DROPS™) for a phase 1 safety and pharmacokinetic study in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of COVI-AMG™.
Initial trial is expected to be followed by a phase 2 trial in both mild and moderate COVID-19 patients, either as a stand-alone nasal application or as a combination nasal and intravenous administration.
Over the last 12 months, SRNE stock rose by 372.50%. The average equity rating for SRNE stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.01 billion, with 251.21 million shares outstanding and 221.63 million shares in the current float. Compared to the average trading volume of 23.47M shares, SRNE stock reached a trading volume of 16013927 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Sorrento Therapeutics Inc. [SRNE]:
H.C. Wainwright have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 31, 2020. While these analysts kept the previous recommendation, Dawson James raised their target price to Buy. The new note on the price target was released on May 26, 2020, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise to $21, while JMP Securities analysts kept a Mkt Outperform rating on SRNE stock.
The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.64, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 48.47. The Price to Book ratio for the last quarter was 9.22.
SRNE Stock Performance Analysis:
Sorrento Therapeutics Inc. [SRNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.21. With this latest performance, SRNE shares dropped by -8.70% in over the last four-week period, additionally plugging by 43.45% over the last 6 months – not to mention a rise of 372.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 52.03, with the RSI for the last a single of trading hit 57.80, and the three-weeks RSI is set at 48.34 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 8.66, while it was recorded at 7.06 for the last single week of trading, and 6.08 for the last 200 days.
Insight into Sorrento Therapeutics Inc. Fundamentals:
Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.20.
SRNE Stock EPS
With the latest financial reports released by the company, Sorrento Therapeutics Inc. posted -0.41/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.
Sorrento Therapeutics Inc. [SRNE] Insider Position Details
There are presently around $547 million, or 28.10% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: BLACKROCK INC. with ownership of 15,016,558, which is approximately 19.758% of the company’s market cap and around 15.71% of the total institutional ownership; STATE STREET CORP, holding 11,708,587 shares of the stock with an approximate value of $88.52 million in SRNE stocks shares; and VANGUARD GROUP INC, currently with $83.94 million in SRNE stock with ownership of nearly 13.661% of the company’s market capitalization.
143 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 16,435,231 shares. Additionally, 73 investors decreased positions by around 5,445,557 shares, while 24 investors held positions by with 50,463,429 shares. The mentioned changes placed institutional holdings at 72,344,217 shares, according to the latest SEC report filing. SRNE stock had 61 new institutional investments in for a total of 2,099,169 shares, while 34 institutional investors sold positions of 1,094,295 shares during the same period.